Scorecard cardiovascular medicine. Its impact and future directions.

PubWeight™: 3.32‹?› | Rank: Top 1%

🔗 View Article (PMID 8250458)

Published in Ann Intern Med on January 01, 1994

Authors

E J Topol1, R M Califf

Author Affiliations

1: Department of Cardiology, Cleveland Clinic Foundation, OH 44195.

Articles by these authors

The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA (1996) 17.62

Evaluating the yield of medical tests. JAMA (1982) 14.05

Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med (2011) 7.62

Regression modelling strategies for improved prognostic prediction. Stat Med (1984) 7.09

Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. N Engl J Med (1994) 6.78

Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators. N Engl J Med (1996) 6.68

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med (1997) 6.19

Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med (1996) 5.94

Racial variation in the use of coronary-revascularization procedures. Are the differences real? Do they matter? N Engl J Med (1997) 5.80

Value of the history and physical in identifying patients at increased risk for coronary artery disease. Ann Intern Med (1993) 5.59

Outcome of acute myocardial infarction according to the specialty of the admitting physician. N Engl J Med (1996) 5.51

A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol (1989) 5.50

Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med (2001) 4.85

Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med (1999) 4.53

Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators. Circulation (2000) 4.46

Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. N Engl J Med (1995) 4.29

Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med (2000) 4.19

1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol (1999) 4.15

Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. Circulation (1999) 4.14

Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med (1995) 3.69

Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med (1991) 3.63

Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation (2000) 3.61

ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol (2000) 3.54

Referral patterns for coronary artery disease treatment: gender bias or good clinical judgment? Ann Intern Med (1992) 3.39

Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation (1995) 3.38

Job strain and the prevalence and outcome of coronary artery disease. Circulation (1995) 3.22

Resuscitation preferences among patients with severe congestive heart failure: results from the SUPPORT project. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Circulation (1998) 3.11

The SUPPORT prognostic model. Objective estimates of survival for seriously ill hospitalized adults. Study to understand prognoses and preferences for outcomes and risks of treatments. Ann Intern Med (1995) 3.08

Prognostic importance of social and economic resources among medically treated patients with angiographically documented coronary artery disease. JAMA (1992) 3.06

A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med (1987) 3.04

ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation (2000) 3.02

Resource use and survival of patients hospitalized with congestive heart failure: differences in care by specialty of the attending physician. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Ann Intern Med (2000) 2.96

Clinical data bases. Accomplishments and unrealized potential. Med Care (1985) 2.83

Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction. N Engl J Med (1996) 2.83

ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol (1996) 2.81

Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. Lancet (1997) 2.80

Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA (1997) 2.77

Comparison of predictions based on observational data with the results of randomized controlled clinical trials of coronary artery bypass surgery. J Am Coll Cardiol (1988) 2.59

1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation (1999) 2.58

Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation (1995) 2.53

Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrument. Ann Intern Med (1997) 2.52

Factors affecting sensitivity and specificity of exercise electrocardiography. Multivariable analysis. Am J Med (1984) 2.49

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet (1994) 2.45

Cardiogenic shock complicating acute coronary syndromes. Lancet (2000) 2.42

Randomised trial of magnesium in in-hospital cardiac arrest. Duke Internal Medicine Housestaff. Lancet (1997) 2.30

Comparison of cefuroxime with or without intranasal fluticasone for the treatment of rhinosinusitis. The CAFFS Trial: a randomized controlled trial. JAMA (2001) 2.29

Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. GUSTO-IIa Investigators. Clin Chem (1998) 2.27

A comparison of U.S. and Canadian cardiac catheterization practices in detecting severe coronary artery disease after myocardial infarction: efficiency, yield and long-term implications. J Am Coll Cardiol (1999) 2.24

Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet (2001) 2.23

Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation (1997) 2.23

Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol (1999) 2.23

Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators. Circulation (1998) 2.09

Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA (1999) 2.08

Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol (1997) 2.08

Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol (1996) 2.07

Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis. J Am Coll Cardiol (1990) 2.06

Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. Eur Heart J (2002) 2.06

The last word on GUSTO, for now. Ann Intern Med (1994) 2.02

Exercise treadmill score for predicting prognosis in coronary artery disease. Ann Intern Med (1987) 1.98

Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. Circulation (1994) 1.91

Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. J Am Coll Cardiol (1996) 1.91

Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Am Heart J (1990) 1.90

Absence of sex bias in the referral of patients for cardiac catheterization. N Engl J Med (1994) 1.90

Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation (1996) 1.87

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation (2001) 1.83

Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol (1997) 1.80

Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J (1999) 1.76

Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. Circulation (1990) 1.74

Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. Eur Heart J (2000) 1.73

Prognostic value of a coronary artery jeopardy score. J Am Coll Cardiol (1985) 1.71

Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol (1993) 1.70

Estimating the likelihood of significant coronary artery disease. Am J Med (1983) 1.69

Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet (1999) 1.68

Advanced coronary artery disease: Appropriate end points for trials of novel therapies. Am Heart J (2001) 1.67

Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators. Circulation (1998) 1.66

Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease. J Thorac Cardiovasc Surg (1996) 1.64

Multivessel coronary artery disease: a key predictor of short-term prognosis after reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Am Heart J (1991) 1.64

Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. J Am Coll Cardiol (2000) 1.63

Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT. Eur Heart J (2000) 1.62

Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol (1997) 1.62

Prognostic value of radionuclide angiography in medically treated patients with coronary artery disease. A comparison with clinical and catheterization variables. Circulation (1990) 1.61

Depression and long-term mortality risk in patients with coronary artery disease. Am J Cardiol (1996) 1.61

Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. Eur Heart J (2004) 1.59

Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation (1999) 1.59

Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J (2001) 1.58

Current prognosis of ischemic mitral regurgitation. Implications for future management. Circulation (1988) 1.57

Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries. Eur Heart J (1999) 1.57

Stroke and acute myocardial infarction in the thrombolytic era: clinical correlates and long-term prognosis. J Am Coll Cardiol (1990) 1.57

Tying clinical research to patient care by use of an observational database. Stat Med (1985) 1.56

Factors associated with change in resuscitation preference of seriously ill patients. The SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Arch Intern Med (1996) 1.56

Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med (1999) 1.55

Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): design and rationale. Am Heart J (2001) 1.55

Comparison of medicine alone, coronary angioplasty, and left internal mammary artery-coronary artery bypass for one-vessel proximal left anterior descending coronary artery disease. Am J Cardiol (2000) 1.54

Recurrent ischemia without warning. Analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator. Circulation (1989) 1.54

Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb Angioplasty Substudy. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes. J Am Coll Cardiol (2000) 1.53

Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation (1998) 1.52

Risk stratification after myocardial infarction. Ann Intern Med (1997) 1.51

Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. J Am Coll Cardiol (2001) 1.51

Lack of progress in cardiogenic shock: lessons from the GUSTO trials. Eur Heart J (2000) 1.50